Evgen Pharma PLC Notice of Preliminary Results (1623G)

TIDMEVG

RNS Number : 1623G

Evgen Pharma PLC

25 May 2017

 
 For immediate release    25 May 2017 
 
 

Evgen Pharma plc

("Evgen Pharma" or "the Company")

Notice of Preliminary Results

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March 2017 on Tuesday 13 June 2017.

A meeting for analysts will be held at 11.00am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For further information, or to register attendance, please contact Buchanan at the contact details below.

Enquiries:

 
 Evgen Pharma plc                              c/o +44 (0) 20 
  Dr Stephen Franklin, CEO                          7466 5000 
  Richard Moulson, CFO 
  www.evgen.com 
 
 Buchanan 
  Mark Court, Sophie Cowles, Stephanie             +44 (0) 20 
  Watson                                            7466 5000 
 
 Northland Capital Partners Limited 
  Matthew Johnson, Gerry Beaney, Margarita 
  Mitropoulou (Corporate Finance) 
  John Howes and Rob Rees (Corporate               +44 (0) 20 
  Broking)                                          3861 6625 
 
 

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORQZLFLDEFXBBB

(END) Dow Jones Newswires

May 25, 2017 02:02 ET (06:02 GMT)